Figure 1From: IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-respondersDistribution of the different IL28B rs12979860 variants according to prior hepatitis C therapy group.Back to article page